Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix has reported Convertible Debt over the past 5 years, most recently at $9.1 million for Q4 2023.

  • For Q4 2023, Convertible Debt fell 68.21% year-over-year to $9.1 million; the TTM value through Dec 2023 reached $9.1 million, down 68.21%, while the annual FY2023 figure was $9.1 million, 68.21% down from the prior year.
  • Convertible Debt for Q4 2023 was $9.1 million at Ocular Therapeutix, up from $8.8 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $30.0 million in Q2 2023 and troughed at $8.8 million in Q3 2023.
  • A 5-year average of $24.3 million and a median of $25.3 million in 2020 define the central range for Convertible Debt.
  • Biggest five-year swings in Convertible Debt: increased 10.27% in 2020 and later tumbled 68.87% in 2023.
  • Year by year, Convertible Debt stood at $24.3 million in 2019, then increased by 0.01% to $24.3 million in 2020, then rose by 8.75% to $26.4 million in 2021, then grew by 8.75% to $28.7 million in 2022, then crashed by 68.21% to $9.1 million in 2023.
  • Business Quant data shows Convertible Debt for OCUL at $9.1 million in Q4 2023, $8.8 million in Q3 2023, and $30.0 million in Q2 2023.